Discussing axSpA: Symptom duration impact on bimekizumab efficacy and therapeutic switching drivers
The IMID Forum
- Published
- March 19, 2026
- Duration
- 33:29
- Summary source
- description
- Last updated
- Jun 21, 2026
Discusses Join Dr Sofia Ramiro and Dr Atul Dheodhar as they discuss the top publications in the world of axSpA…
Summary
Join Dr Sofia Ramiro and Dr Atul Dheodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the impact of shorter versus longer symptom duration on the efficacy of bimekizumab and the factors associated with therapeutic switching in SpA.
Intelligent report
Sign in to read teasers, or upgrade to Research Pro to commission a new dossier for this episode. Learn more →
Show notes
Join Dr Sofia Ramiro and Dr Atul Dheodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the impact of shorter versus longer symptom duration on the efficacy of bimekizumab and the factors associated with therapeutic switching in SpA.